Share

Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award

Congratulations to our longstanding member Dr. Hans Wildiers for receiving the B.J. Kennedy Geriatric Oncology Award at the 2023 ASCO Annual Meeting.

Created in 2007 in honour of B.J. Kennedy, MD, this award recognises an ASCO member who has made outstanding contributions to the research, diagnosis, and treatment of cancer in the elderly, and in bringing an understanding of geriatric oncology to fellows and junior faculty.

During the Award Lecture (session available on-demand for participants), Dr. Wildiers presented a session titled “Looking Back and Moving Forward” where he focused on the achievements in the field of geriatric oncology and the work that is still needed to improve the care of older patients with cancer.

During his presentation, he thanked organisations like EORTC, which have strongly supported geriatric oncology research in the last years.

“It is my great honour to receive this year’s the B.J. Kennedy Geriatric Oncology Award. […] Within the EORTC, we had a lot of discussions on the optimal trial design for older patients with cancer.”

– Dr. Hans Wildiers

Dr. Wildiers is a medical oncologist dedicated to breast cancer research. He has served as a staff member in the Department of Medical Oncology at the University Hospital Leuven, Belgium, since 2004. Since 2015, he has been the coordinator of the Leuven Multidisciplinary Breast Center. He has also been the coordinator of several academic studies in the field of breast cancer and geriatric oncology and is the author of more than 350 peer-reviewed papers. He has been active on the Board of the International Society of Geriatric Oncology for many years and served as the organisation’s president from 2018 to 2020. From 2009 to 2015, he chaired the Cancer in the Elderly Task Force of the European Organisation for Research and Treatment of Cancer (EORTC).

More information here.

Back to news list

Related News

  • Meet the new EORTC Board

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)